Equities

Celldex Therapeutics Inc

Celldex Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)27.06
  • Today's Change0.84 / 3.20%
  • Shares traded208.25k
  • 1 Year change-2.49%
  • Beta1.5808
Data delayed at least 15 minutes, as of Nov 22 2024 18:18 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy5
Outperform5
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for Celldex Therapeutics, Inc. have a median target of 69.00, with a high estimate of 90.00 and a low estimate of 42.00. The median estimate represents a 163.16% increase from the last price of 26.22.
High243.2%90.00
Med163.2%69.00
Low60.2%42.00

Earnings history & estimates in USD

On Nov 06, 2024, Celldex Therapeutics, Inc. reported 3rd quarter 2024 losses of -0.64 per share. This result was in line with the consensus of the 11 analysts following the company and exceeded last year's 3rd quarter results by 20.99%.
The next earnings announcement is expected on Feb 24, 2025.
Average growth rate+3.78%
Celldex Therapeutics, Inc. reported annual 2023 losses of -2.92 per share on Feb 26, 2024.
Average growth rate-1.69%
More ▼

Revenue history & estimates in USD

Celldex Therapeutics, Inc. had 3rd quarter 2024 revenues of 3.19m. This bettered the 828.00k consensus of the 10 analysts covering the company. This was 229.99% above the prior year's 3rd quarter results.
Average growth rate+401.29%
Celldex Therapeutics, Inc. had revenues for the full year 2023 of 6.88m. This was 192.02% above the prior year's results.
Average growth rate+53.25%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.